Abstract Gain of chromosome 1q (+ 1q) is one of the most common recurrent cytogenetic
abnormalities in multiple myeloma (MM), occurring in approximately 40% of newly …

Multiple myeloma is characterized by underlying clinical and biological heterogeneity, which
translates to variable response to treatment and outcome. With the recent increase in …

Purpose The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and
reliable tool is needed to stratify patients with MM. We combined the International Staging …

Background Patients with multiple myeloma treated with lenalidomide maintenance therapy
have improved progression-free survival, primarily following autologous stem-cell …

Abstract The International Myeloma Working Group consensus updates the definition for
high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities …

Purpose At the molecular level, myeloma is characterized by copy number abnormalities
and recurrent translocations into the immunoglobulin heavy chain locus. Novel methods …

Owing to increasing resistance and the limited arsenal of new antibiotics, especially against
Gram-negative pathogens, carefully designed antibiotic regimens are obligatory for febrile …

Based on the clinical features of myeloma and related malignancies of plasma cells, it has
been possible to generate a model system of myeloma progression from a normal plasma …

Abstract Gain of chromosome 1q (+ 1q) is commonly identified in multiple myeloma and has
been associated with inferior outcomes. However, the prognostic implication of+ 1q has not …

Summary The anti-FcRH5/CD3 T cell-dependent bispecific antibody (TDB) targets the B cell
lineage marker FcRH5 expressed in multiple myeloma (MM) tumor cells. We demonstrate …